WinstonWınston
Smith & Nephew logo

Smith & Nephew

SNN
59
Medical - Devices · Healthcare
Price
$30.43
-0.16 (-0.52%)
Market Cap
$12.83B
Exchange
New York Stock Exchange
Winston Score
59
Winston is curious
A decent business — some strong pillars, some weaker.

Smith & Nephew is a British medical device company that makes products used by surgeons and doctors to repair and replace damaged body parts. Its three main business areas are orthopedics (knee and hip replacements), sports medicine and joint repair (tools to fix torn ligaments and cartilage), and advanced wound management (bandages and dressings for hard-to-heal wounds). Hospitals, surgeons, and healthcare systems around the world are its main customers.

The company earns money by selling its devices and consumable products directly to hospitals, with recurring revenue coming from the ongoing need for wound care supplies and surgical tools. Smith & Nephew operates globally, with significant revenue from the US, Europe, and emerging markets, and generates roughly $5 billion in annual revenue. Its competitive position relies on strong surgeon relationships and a broad product portfolio, but it faces pressure from larger rivals like Stryker and Zimmer Biomet, and improving its operational efficiency remains a key challenge for sustaining growth.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+7.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+69.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$297M/ year

Flat (+3% vs prior year)

4.8% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.2%ownership

Relatively low insider ownership

Cash Position

Cash flow positive

$708M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Smith & Nephew is growing revenue at 7% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

0.5% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 438.9M (2021) → 436.5M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
65.6%
Premium pricing power — 65.6% gross margin
Operating Margin
17.9%
Healthy — 17.9% operating margin
ROCE
6.8%
Weak — 6.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+6.3%
Slow sales growth (6.3% YoY)
EPS YoY
+52.1%
Earnings growing fast (52.1% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
206%
Turns 206% of profit into real cash
FCF Margin
13.8%
Converts sales into free cash efficiently (13.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.59
Conservative — low debt load (0.59)
Interest Cover
6.43x
Adequate interest coverage (6.4x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
20.8x
Growth-priced — P/E 20.8

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+9.7
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (20.8 → 11.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
2.52%
Moderate income — 2.52% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth
+2.8%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial